Resumen
Objetivo: Correlacionar los resultados de las pruebas autocolectadas de ADN-HPV con los cambios citológicos e histológicos en pacientes de una clínica especializada. Metodos: Se trata de un estudio retrospectivo, cuantitativo, transversal, descriptivo y observacional realizado con pacientes de 25 a 64 años en una clínica de colposcopía de un hospital público en el Distrito Federal. Las pacientes presentaron alteraciones en citologías oncológicas y fueron sometidas a la prueba autocolectada de ADN-HPV entre mayo de 2023 y mayo de 2024. Resultados: De las 191 pacientes incluidas en el estudio, el 57,1% tenían entre 30 y 49 años. La prueba de ADN-HPV fue detectada en el 65,4% de los casos. Entre las pacientes con resultado positivo para ADN-HPV, el hallazgo histopatológico más prevalente fue NIC2/3. Esta relación fue estadísticamente significativa en las pacientes de 30 a 49 años (valor p 0,049) y mayores de 50 años (valor p 0,006), pero no en las pacientes menores de 29 años (valor p 0,164). Conclusión: La prueba de HPV puede ser utilizada para guiar el tratamiento de pacientes con citologías alteradas, seleccionando así a aquellas que requieren medidas más o menos invasivas.
Referencias
ALI M, et al. HPV DNA status and clinical history of patients are supplements for accurate reporting of the cytological Pap smear. Sci Rep., 2024; 14: 174-186.
ARBYN M, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol., 2014; 15(2): 172–183.
AUSTRALIAN INSTITUTE OF HEALTHCARE AND WELFARE. Cervical screening in Australia. 2019.
BRASIL. Diretrizes Brasileiras para o Rastreamento do Câncer do Colo de útero. Rio de Janeiro: INCA, 2016; 2.
CARVALHO CF, et al. Cervical Cancer Screening with HPV testing: Updates on the recommendation. Rev Bras Ginecol Obstet., 2022; 44(3): 264–271.
CHAN KKL, et al. PAX1/SOX1 DNA methylation versus cytology and HPV16/18 genotyping for the triage of high-risk HPV-positive women in cervical cancer screening: Retrospective analysis of archival samples. BJOG, 2025; 132: 197-204.
DIMITROVA M, et al. Economic consequences of the implementation of primary DNA-HPV genotype testing in Bulgaria. Biotechnol Biotechnol Equip., 2024; 38(1): 2358134.
EFFAH K, et al. Cervical precancer screening using self-sampling, HPV DNA testing, and mobile colposcopy in a hard-to-reach community in Ghana: a pilot study. BMC Cancer, 2024; 24: 1367.
EKAWATI FM, et al. Cervical cancer screening program in Indonesia: is it time for HPV-DNA tests? Results of a qualitative study exploring the stakeholders’ perspectives. BMC Women's Health, 2024; 24: 125.
FONSECA FV, et al. Cervical Intraepithelial Neoplasia: Analyzing the Disease Present Exclusively in the Endocervical Canal. Revista Brasileira de Ginecologia e Obstetrícia, 2022; 44(4): 385–390.
GRCE M, DAVIES P. Human papillomavirus testing for primary cervical cancer screening. Expert Review of Molecular Diagnostics 2008; 8(5): 599-605.
GUPTA C, et al. Evaluating different samples & techniques for hr-HPV DNA genotyping to improve the efficiency of risk profiling for oral & cervical cancers in Sikkim, India. Indian J Med Res., 2024; 160(2): 226-235.
JANSEN EEL, et al. Effect of organisef cervical cancer mortality in Europe: a systematic review. Eur J Cancer, 2020; 127: 207-223.
JUNG Y, et al. Clinical factors that affect diagnostic discrepancy between colposcopically directed biopsies and loop electrosurgical excision procedure conization of the uterine cervix. Obstet Gynecol Sci., 2018; 61(4): 477–483.
KITTISIAM T, et al. Clinical Performance of Self-collected Specimen HPV-DNA vs Clinician-collected Specimen HPV-mRNA to Detect High-risk HPV and High-grade Cervical Lesions and Cancer. Asian Pac J Cancer Prev., 2024; 25(1): 211-217.
LIM LM, et al. Self-sampling HPV DNA test for cervical cancer screening in Singapore: A prospective study. Ann Acad Med Singap., 2022; 51(11): 733–735.
ARAUJO ACM, et al. Nota Técnica No 41/2024-CGICI/DPNI/SVSA/MS. 2024.
MIGLIORELLI A, et al. Circulating HPV Tumor DNA and Molecular Residual Disease in HPV-Positive Oropharyngeal Cancers: A Scoping Review. Diagnostics, 2024; 14(23): 2662.
OKADA PA, et al. External quality assessment program for human papillomaviruses DNA testing in Thailand. Pract Lab Med., 2024; 38: e00352.
PERERA KCM, et al. Prevalence of vaginal and cervical HPV infection among 35-year age cohort ever-married women in Kalutara district of Sri Lanka and the validity of vaginal HPV/DNA specimen as a cervical cancer screening tool: a cross-sectional study. BMC Infect Dis., 2024; 24: 1249.
PEREIRA NCF, et al. Sobretratamento excisional ambulatorial do colo uterino: histologia negativa para atipias. Revista Eletrônica Acervo Saúde, 2024; 24(2): e15936.
PRZYBYLSKI M, et al. Evaluation of Automatic Signal Detection of In Situ Hybridization for Detecting HPV DNA in Cervical Tissue Derived from Patients with Cervical Intraepithelial Neoplasia. Cancers (Basel), 2024; 16(20): 3485.
SANTI M, et al. Prevalence of hr-HPV genotypes among vaccinated and unvaccinated women in central Italy: a retrospective study. Acta Biomed., 2024.
SCHIFFMAN M, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers, 2016; 2: 16086.
SCHEIBERHUBER L, et al. Cervical cancer screening using DNA methylation triage in a real-world population. Nat Med., 2024; 30(8): 2251-2257.
TEIXEIRA JC, et al. Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol. BMC Public Health, 2020; 20: 576.
TEIXEIRA JC, et al. Cervical Cancer Screening with DNA-HPV Testing and Precancerous Lesions Detection: A Brazilian Population-based Demonstration Study. Rev Bras Ginecol Obstet., 2023; 45(1): 21–30.
TEIXEIRA JC, et al. Transition from opportunistic cytological to organized screening program with DNA-HPV testing detected prevalent cervical cancers 10 years in advance. Sci Rep., 2024; 14: 20761.
TERÁN-FIGUEROA Y, et al. Coleta de amostra para identificação de DNA do papilomavírus: conhecimento e habilidades. Acta Paul Enferm., 2019; 32(5): 514-20.
WRIGHT TC, et al. "The ATHENA Human Papillomavirus Study: The Impact of HPV Testing on Clinical Management of Cervical Cytology Abnormalities." Obstetrics & Gynecology, 2015; 126(3): 453-459.
WORLD HEALTH ORGANIZATION. Comprehensive Cervical Cancer Control: A guide to essential practice. WHO Library; 2021.
ZHOU Y, et al. Correlations between C-myc expression, BMI-1 expression, and vaginal microecology with HPV-DNA load in patients with different cervical lesions. Am J Transl Res., 2024; 16(6): 2544-2553.
